← Back to all trials
Recruiting
NCT07484269
PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan
Conditions: Metastatic Prostate Cancer
Sex: Male
Healthy volunteers: No
Enrollment: 753
Sponsor: Novartis Pharmaceuticals
Location: Novartis Investigative SIte Basel
Summary
The primary objective of the study is to describe real-world drug utilisation of lutetium (177Lu) vipivotide tetraxetan among patients with metastatic prostate cancer
Eligibility Criteria
Inclusion criteria:
Age ≥ 18 years at index date
* Diagnosis of mPC
* PSMA positive
* Received at least one dose of lutetium (177Lu) vipivotide tetraxetan on or after mPC diagnosis date
Exclusion criterion:
• Current or prior participation in an investigational study within the 30-day period immediately prior to and including the index date, or within five half-lives of the investigational product (whichever is longer)
Source: ClinicalTrials.gov (NCT07484269). StuddyBuddy aggregates publicly available trial information.
